Male, 62 y/o

Patient internal ID: 102389711

ICD-10 code

C34.1 Malignant Neoplasm of Upper Lobe, Bronchus or Lung

Diagnosis (incl metastases/stage) and year

December 2010
Carcinoma of Upper Lobe of Right Lung pT1a N0M0R0 G2 I st.
May 2020 disease progression.
Pleomorphic Carcinoma of the Lung with Partial Neuroendocrine Differentiation with Metastasis in both Lungs pT1aNxM1.

Previous treatment

Surgery (Segmentectomy), Target Therapy (Erlotinib), Radiation Therapy, Surgery (Segmentectomy – 2nd), Chemotherapy (Carboplatin, Paclitaxel), Chemotherapy (Gemcitabine).

Prognosis and survival expectation

The prognosis remains poor, with a median survival of ~1 year from diagnosis.

Treatment provided

Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months.
Additionally, the patient received Umbilical Cord Blood Derived NK cells (8 doses).

Patient survival/condition and year

After the disease progression, the patient survived for 3 years.
It can be concluded that Immunotherapy, alongside Surgery, Chemotherapies and Radiation Therapy, has extended the patient’s survival by around 2 years compared with median survival.

Date of Review